View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 26, 2018

Italian researchers develop breast cancer imaging device

Researchers at Politecnico di Milano, Italy have developed an optical mammography (OM) instrument that uses harmless red or infrared light for diagnostic imaging or monitoring of breast cancer patients.

Researchers at Politecnico di Milano, Italy have developed an optical mammography (OM) instrument that uses harmless red or infrared light for diagnostic imaging or monitoring of breast cancer patients.

The device is meant to be used in combination with X-rays to avoid high ionising radiation in people who require repeated imaging. It has been developed under the Smart Optical and Ultrasound Diagnostics of Breast Cancer (SOLUS) project.

Instead of two photomultiplier tubes (PMTs) seen in current X-ray mammography devices, the new instrument contains an eight-channel probe with silicon photomultipliers (SiPMs) and a multichannel time-to-digital converter.

“The device is meant to be used in combination with X-rays to avoid high ionising radiation in people who require repeated imaging.”

The latest additions are intended to avoid a time-consuming pre-scan commonly performed to not damage the PMTs, and are said to be responsible for the increased sensitivity and decreased expenses.

Optical imaging methods can be used to analyse tissue composition, including measurement of blood volume, oxygenation, lipid, water and collagen content in a suspected area identified using conventional X-ray imaging technique.

However, OM imaging lacks in the spatial resolution area and its combination with other imaging approaches is expected to address this challenge.

OM instruments also require the exertion of gentle pressure or some need none at all as they work by employing rings of light sources and detectors. OM is considered best applicable in pre-surgical chemotherapy.

Research co-author Edoardo Ferocino said: “This technique is able to provide information on the outcome of chemotherapy just weeks after beginning treatment, or possibly even sooner.”

Ferocino and his team intend to further study the applications of OM in monitoring and predicting chemotherapy outcomes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU